{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:03:25Z","timestamp":1778771005347,"version":"3.51.4"},"reference-count":20,"publisher":"Institute of Biochemistry","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Sepsis-associated encephalopathy (SAE) is a condition characterized by acute brain dysfunction developed in the absence of a primary infection in the central nervous system. The aim of this study was to perform a pilot, untargeted metabolomic profiling of the blood plasma of SAE patients to identify metabolic changes potentially associated with the pathological condition and to generate hypotheses for further studies of its pathogenesis, as well as to the search for promising biomarkers, and the assessment of the severity of the patient's condition. Metabolomic profiling was performed using HPLC-HR-MS, followed by statistical analysis of the obtained data. This blinded, randomized, controlled clinical trial revealed significant differences in the metabolic profiles of the study and control groups. Functional analysis showed the metabolic pathways most affected by pathological processes in SAE patients. These included metabolism of acylcarnitines, lysophosphatidylcholines, and taurine, folate biosynthesis, and the drug metabolism involving the cytochrome P450 pathway. In SAE patients with impaired consciousness, including delirium and coma, decreased levels of long-chain acylcarnitines and lysophosphatidylcholines were observed. The metabolomic profiles of SAE patients differed significantly between the groups of deceased and surviving patients: concentrations of sulfur-containing amino acids were significantly lower in the group of deceased than in the group of survivors. Our study identified 64 candidate biomarkers that could potentially be used to predict sepsis outcomes. However, further study is needed using an expanded and independent cohort of patients.<\/jats:p>","DOI":"10.18097\/pbmcr1599","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:29:59Z","timestamp":1764250199000},"page":"441-453","source":"Crossref","is-referenced-by-count":2,"title":["Metabolomic profiling of patients with sepsis-associated encephalopathy"],"prefix":"10.18097","volume":"71","author":[{"given":"E.D.","family":"Kessenikh","sequence":"first","affiliation":[{"name":"Almazov National Medical Research Centre, Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.M.","family":"Bykova","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre, Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.A.","family":"Murashko","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre, Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya.A.","family":"Dubrovskii","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre, Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.V.","family":"Dorofeykov","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre, Saint Petersburg, Russia; Lesgaft National State University of Physical Education, Sport and Health, Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.A.","family":"Savvina","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre, Saint Petersburg, Russia; North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7443","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Hu J., Xie S., Xia W., Huang F., Xu B., Zuo Z., Liao Y., Qian Z., Zhang L. (2024) Meta-analysis of evaluating neuron specific enolase as a serum biomarker for sepsis-associated encephalopathy. Int. Immunopharmacol., 131, 111857.","DOI":"10.1016\/j.intimp.2024.111857"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Havelund J., Heegaard N., F\u00e6rgeman N., Gramsbergen J. (2017) Biomarker research in Parkinson\u2019s disease using metabolite profiling. Metabolites, 7(3), 42.","DOI":"10.3390\/metabo7030042"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Trongtrakul K., Thonusin C., Pothirat C., Chattipakorn S.C., Chattipakorn N. (2021) Past experiences for future applications of metabolomics in critically ill patients with sepsis and septic shocks. Metabolites, 12(1), 1.","DOI":"10.3390\/metabo12010001"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Hussain H., Vutipongsatorn K., Jim\u00e9nez B., Antcliffe D.B. (2022) Patient stratification in sepsis: using metabolomics to detect clinical phenotypes, sub-phenotypes and therapeutic response. Metabolites, 12(5), 376.","DOI":"10.3390\/metabo12050376"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Liu J., Zhou G., Wang X., Liu D. (2022) Metabolic reprogramming consequences of sepsis: adaptations and contradictions. Cell. Mol. Life Sci., 79(8), 456.","DOI":"10.1007\/s00018-022-04490-0"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Dryagina N.V., Kondratyeva E.A., Dubrovskii Ya.A., Kondratyev A.N. (2020) Metabolome of the brain. Russian Neurological Journal, 25(1), 4\u201312.","DOI":"10.30629\/2658-7947-2020-25-1-4-12"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Khan S., Ince-Dunn G., Suomalainen A., Elo L.L. (2020) Integrative omics approaches provide biological and clinical insights: examples from mitochondrial diseases. J. Clin. Invest., 130(1), 20\u201328.","DOI":"10.1172\/JCI129202"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Smirnov K.S., Maier T.V., Walker A., Heinzmann S.S., Forcisi S., Martinez I., Walter J., Schmitt-Kopplin P. (2016) Challenges of metabolomics in human gut microbiota research. Int. J. Med. Microbiol., 306(5), 266\u2013279.","DOI":"10.1016\/j.ijmm.2016.03.006"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Xi B., Gu H., Baniasadi H., Raftery D. (2014) Statistical analysis and modeling of mass spectrometry-based metabolomics data. In: Mass Spectrometry in Metabolomics (Raftery D., ed.), Springer New York (Methods in Molecular Biology), New York, NY, pp. 333\u2013353.","DOI":"10.1007\/978-1-4939-1258-2_22"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"McCann M.R., George de la Rosa M.V., Rosania G.R., Stringer K.A. (2021) L-Carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine. Metabolites, 11(1), 51.","DOI":"10.3390\/metabo11010051"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Qu Q., Zeng F., Liu X., Wang Q.J., Deng F. (2016) Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis., 7(5), e2226.","DOI":"10.1038\/cddis.2016.132"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Musso G., Saba F., Cassader M., Gambino R. (2023) Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): recent advances. Prog. Lipid Res., 91, 101238.","DOI":"10.1016\/j.plipres.2023.101238"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Farooqui A.A., Horrocks L.A., Farooqui T. (2000) Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids, 106(1), 1\u201329.","DOI":"10.1016\/S0009-3084(00)00128-6"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Farooqui A.A., Horrocks L.A., Farooqui T. (2007) Modulation of inflammation in brain: a matter of fat. J. Neurochem., 101(3), 577\u2013599.","DOI":"10.1111\/j.1471-4159.2006.04371.x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Trofimova N.V., Andropova T.N., Talybov R.S., Sebelev K.I., Potemkina E.G., Ryzhkov A.V. (2024) Neuroradiology of sepsis-associated encephalopathy. In: Sepsis-Associated Encephalopathy: Clinical, Metabolomic, Neurophysiological and Neuroimaging Parallels (Savvina I.A., Beloborodova N.V., Trofimova T.N., eds.), Nova Science Publishers, New York, pp. 109\u2013138.","DOI":"10.52305\/QQGR0434"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kodentsova V.M., Risnik D.V., Ladodo O.B. (2022) Functional ingredient taurine: adequate and clinically effective doses. Meditsinskiy Sovet, 16(14), 88\u201395.","DOI":"10.21518\/2079-701X-2022-16-14-88-95"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Serkova N.J., Standiford T.J., Stringer K.A. (2011) The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. Am. J. Respir. Crit. Care Med., 184(6), 647\u2013655.","DOI":"10.1164\/rccm.201103-0474CI"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Su L., Huang Y., Zhu Y., Xia L., Wang R., Xiao K., Wang H., Yan P., Wen B., Cao L., Meng N., Luan H., Liu C., Li X., Xie L. (2014) Discrimination of sepsis stage metabolic profiles with an LC\/MS-MS-based metabolomics approach. BMJ Open Respir. Res., 1(1), e000056.","DOI":"10.1136\/bmjresp-2014-000056"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Puskarich M.A., Finkel M.A., Karnovsky A., Jones A.E., Trexel J., Harris B.N., Stringer K.A. (2015) Pharmacometabolomics of L-carnitine treatment response phenotypes in patients with septic shock. Ann. Am. Thorac. Soc., 12(1), 46\u201356.","DOI":"10.1513\/AnnalsATS.201409-415OC"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Cambiaghi A., Pinto B.B., Brunelli L., Falcetta F., Aletti F., Bendjelid K., Pastorelli R., Ferrario M. (2017) Characterization of a metabolomic profile associated with responsiveness to therapy in the acute phase of septic shock. Sci. Rep., 7, 9748.","DOI":"10.1038\/s41598-017-09619-x"}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T10:14:37Z","timestamp":1766657677000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2025-71-6-441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmcr1599","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}